Safe injection sites, also called supervised consumption sites, do work by the measures most commonly used to evaluate them. Across decades of operation in Canada, Europe, and Australia, no one has ever died of an overdose inside a legally sanctioned site. Beyond that headline number, the evidence shows these facilities reduce infectious disease transmission, connect people to addiction treatment, lower healthcare costs, and decrease drug-related litter in surrounding neighborhoods.
The Overdose Safety Record
The most striking data point is the simplest one. Overdoses happen at supervised consumption sites at a rate of roughly 1 per 1,000 injections, but trained staff reverse them on the spot. Between 2017 and 2024, federally approved sites in Canada alone responded to more than 60,000 overdose events. Not a single person died on site. That record holds across every legally operating facility worldwide.
This matters because the alternative is people using alone or in alleys, cars, and public restrooms where no one can intervene. In those settings, an overdose that goes unwitnessed for even a few minutes can be fatal, especially with fentanyl now contaminating much of the drug supply.
Impact on HIV and Hepatitis C
Sharing needles is the primary way blood-borne infections spread among people who inject drugs. Supervised consumption sites provide clean equipment and a space where sharing becomes unnecessary. Research based on U.S. data found that access to these facilities reduced needle sharing dramatically, cutting the risk by roughly 83%.
A modeling study across three California counties estimated what would happen if just 20% of people who inject drugs used a supervised site. Over ten years, San Francisco could prevent about 22% of new HIV infections and 28% of new hepatitis C infections among that population. Los Angeles showed similar projections: around 18% fewer new HIV cases and 30% fewer hepatitis C cases. San Diego’s estimates were even higher for HIV prevention, at 32%. These aren’t theoretical benefits in countries with different healthcare systems. They’re projections built on American data for American cities.
Connection to Addiction Treatment
A common criticism is that safe injection sites enable drug use without helping people quit. The evidence points in the opposite direction. A systematic review of supervised injection facilities found that seven separate studies linked these sites to significant improvements in access to addiction treatment programs.
People who used Vancouver’s supervised injection facility frequently were 1.4 to 1.7 times more likely to enter detox or treatment compared to infrequent or nonusers. A study of facilities in Spain found that frequent visitors had roughly twice the odds of accessing addiction treatment in the previous six months. The explanation is straightforward: these sites employ healthcare workers and counselors who build trust with a population that largely avoids traditional medical settings. Once that relationship exists, conversations about treatment become possible.
Most sites offer far more than a clean table and a nurse watching for overdoses. Services typically include drug checking to detect fentanyl and other adulterants, wound care, testing for HIV and hepatitis C, mental health support, medications for opioid use disorder, and referrals to treatment and housing programs. They function as a front door to a healthcare system that many people who use drugs otherwise never walk into.
Healthcare Cost Savings
Every overdose managed inside a supervised site is one that doesn’t require an ambulance and an emergency room visit. A cost analysis of a site in Alberta, Canada, calculated that each overdose handled on site saved approximately $1,600 in emergency costs: $385 for the ambulance ride and $1,061 for the emergency department visit, plus related expenses. Over the program’s lifetime, that single site generated over $2.3 million in savings by keeping overdose patients out of the ER.
These figures don’t account for the longer-term savings from preventing HIV and hepatitis C infections, which cost hundreds of thousands of dollars per person to treat over a lifetime, or from reducing hospitalizations for injection-related infections like endocarditis and abscesses.
Effects on Surrounding Neighborhoods
Neighborhood impact is often the most heated part of the debate. Residents near proposed sites worry about increased crime, loitering, and discarded needles. The available evidence suggests the opposite tends to happen. A study of Dublin’s supervised injecting facility found a 20% reduction in discarded needles within 500 meters of the site, with each additional client attending associated with a further 5% decrease. Drug-related litter by weight dropped 59%, and loitering near the facility declined by 45%.
The logic is simple: if people have a designated indoor space to use drugs, fewer of them do it on sidewalks and in parks. Public injecting was rare both before and after Dublin’s facility opened, staying at essentially the same negligible level. Crack pipes found in the area also declined by 20%.
Legal Status in the United States
Despite the evidence, supervised consumption sites occupy a legal gray area in the U.S. The federal government has historically argued that these facilities violate the “crack house” provision of the Controlled Substances Act, which makes it illegal to maintain a space for the purpose of using drugs. In 2019, a federal judge in Philadelphia ruled that a nonprofit’s plan to open a site did not violate that statute, reasoning that Congress never intended the law to criminalize healthcare interventions. The Justice Department appealed.
New York City opened the country’s first publicly recognized overdose prevention centers in late 2021, operating under city and state authorization rather than federal approval. The legal landscape continues to shift as cities including San Francisco and Seattle have explored or pursued similar programs. Canada, by contrast, has had a federal exemption process in place for years, and dozens of sites operate legally across the country. Europe has more than 100 facilities spread across the Netherlands, Germany, Switzerland, Spain, Denmark, France, and other countries, some dating back to the 1980s.
What the Evidence Does and Doesn’t Show
The strongest evidence is for what happens inside and immediately around the sites: zero deaths on premises, fewer discarded needles, reduced emergency calls, and more people entering treatment. The evidence on broader population-level effects, like whether a city’s overall overdose death rate drops after opening a site, is harder to pin down. Overdose deaths are driven by many factors, including the drug supply, housing instability, and access to treatment, and isolating the effect of a single intervention at the population level is methodologically difficult.
What the research consistently shows is that supervised consumption sites do exactly what they’re designed to do. They keep people alive on their worst days and create a pathway toward treatment when they’re ready for it. They don’t solve the addiction crisis on their own, and no serious advocate claims they do. They’re one component of a broader harm reduction strategy, and by their own specific measures, they work.